Skip to main content
Top
Published in: International Journal of Clinical Oncology 5/2011

01-10-2011 | Original Article

Clinicopathological features of triple-negative breast cancer in Taiwanese women

Authors: Kuo Yao-Lung, Chen Dar-Ren, Chang Tsai-Wang

Published in: International Journal of Clinical Oncology | Issue 5/2011

Login to get access

Abstract

Background

The goal of this study was to identify prognostic factors that influence the survival outcome of Taiwanese women with triple-negative breast cancer (TNBC).

Methods

Of 709 patients with breast cancer diagnosed between January 2002 and December 2005, 152 patients (21.4 %) were diagnosed with TNBC. The overall survival and disease-free survival were estimated using the Kaplan–Meier method and compared between groups using the log-rank test. Univariate and multivariate analyses were used to identify the prognostic factors, and the prognostic significance of these factors in TNBC patients was reviewed.

Results

The median follow-up time was 70.5 months. Kaplan–Meier analysis showed significant difference between the tumor subgroups (TNBC vs. non-TNBC) in 5-year overall survival (p = 0.01) and 5-year disease-free survival (p < 0.0001). Univariate analysis showed that tumor subgroup (TNBC vs. non-TNBC) was a significant predictor of 5-year overall survival and disease-free survival. Tumor size, lymph node status, stage, grade, estrogen receptor status, progesterone receptor status, and HER2 status were also significant. In the multivariate analysis, only tumor size, lymph node status, and grade were significantly related to 5-year overall survival and disease-free survival. In TNBC patients, nodal status was significantly related to 5-year overall survival (HR = 7.47, p < 0.0001) and 5-year disease-free survival (HR = 3.913, p = 0.001).

Conclusion

In TNBC, nodal status is a prognostic indicator of survival. The TNBC subgroup had a worse pattern of relapse compared to the non-TNBC, irrespective of nodal negative or nodal positive breast cancer patients. We suggest that this subgroup should receive aggressive treatment to prevent early recurrence or death. Further prospective clinical trials are warranted to identify a more efficient treatment regimen to improve the prognosis.
Literature
1.
go back to reference Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150PubMedCrossRef Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150PubMedCrossRef
2.
go back to reference Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235–244PubMedCrossRef Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235–244PubMedCrossRef
3.
go back to reference Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312PubMedCrossRef Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312PubMedCrossRef
4.
go back to reference Rhee J, Han SW, Oh DY et al (2008) The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 8:307PubMedCrossRef Rhee J, Han SW, Oh DY et al (2008) The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 8:307PubMedCrossRef
5.
go back to reference Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434PubMedCrossRef Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434PubMedCrossRef
6.
go back to reference Lund MJ, Trivers KF, Porter PL et al (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113:357–370PubMedCrossRef Lund MJ, Trivers KF, Porter PL et al (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113:357–370PubMedCrossRef
7.
go back to reference Lin C, Chien SY, Chen LS et al (2009) Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer 9:192PubMedCrossRef Lin C, Chien SY, Chen LS et al (2009) Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer 9:192PubMedCrossRef
8.
go back to reference Cunningham JE, Montero AJ, Garrett-Mayer E et al (2009) Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes Control 21:399–409PubMedCrossRef Cunningham JE, Montero AJ, Garrett-Mayer E et al (2009) Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes Control 21:399–409PubMedCrossRef
9.
go back to reference Trivers KF, Lund MJ, Porter PL et al (2009) The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 20:1071–1082PubMedCrossRef Trivers KF, Lund MJ, Porter PL et al (2009) The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 20:1071–1082PubMedCrossRef
10.
go back to reference Brower V (2009) Search for new treatments intensifies for triple-negative breast cancer. J Natl Cancer Inst 101:1536–1537PubMedCrossRef Brower V (2009) Search for new treatments intensifies for triple-negative breast cancer. J Natl Cancer Inst 101:1536–1537PubMedCrossRef
11.
go back to reference Woodward WA, Strom EA, Tucker SL et al (2003) Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 21:3244–3248PubMedCrossRef Woodward WA, Strom EA, Tucker SL et al (2003) Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 21:3244–3248PubMedCrossRef
12.
go back to reference Singletary SE, Greene FL (2003) Revision of breast cancer staging: the 6th edition of the TNM Classification. Semin Surg Oncol 21:53–59PubMedCrossRef Singletary SE, Greene FL (2003) Revision of breast cancer staging: the 6th edition of the TNM Classification. Semin Surg Oncol 21:53–59PubMedCrossRef
13.
go back to reference Singletary SE, Allred C, Ashley P et al (2003) Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 83:803–819PubMedCrossRef Singletary SE, Allred C, Ashley P et al (2003) Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 83:803–819PubMedCrossRef
14.
go back to reference Akiyama F, Iwase H (2009) Triple negative breast cancer: clinicopathological characteristics and treatment strategies. Breast Cancer 16:252–253PubMedCrossRef Akiyama F, Iwase H (2009) Triple negative breast cancer: clinicopathological characteristics and treatment strategies. Breast Cancer 16:252–253PubMedCrossRef
15.
go back to reference Iwase H, Kurebayashi J, Tsuda H et al (2009) Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer 17:118–124PubMedCrossRef Iwase H, Kurebayashi J, Tsuda H et al (2009) Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer 17:118–124PubMedCrossRef
16.
go back to reference Yin WJ, Lu JS, Di GH et al (2009) Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 115:325–333PubMedCrossRef Yin WJ, Lu JS, Di GH et al (2009) Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 115:325–333PubMedCrossRef
17.
go back to reference Bosch A, Eroles P, Zaragoza R et al (2010) Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 36:206–215PubMedCrossRef Bosch A, Eroles P, Zaragoza R et al (2010) Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 36:206–215PubMedCrossRef
18.
go back to reference Dawson SJ, Provenzano E, Caldas C (2009) Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 45(Suppl 1):27–40PubMedCrossRef Dawson SJ, Provenzano E, Caldas C (2009) Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 45(Suppl 1):27–40PubMedCrossRef
19.
go back to reference Tischkowitz M, Brunet JS, Begin LR et al (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134PubMedCrossRef Tischkowitz M, Brunet JS, Begin LR et al (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134PubMedCrossRef
20.
go back to reference Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657PubMedCrossRef Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657PubMedCrossRef
21.
go back to reference Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281PubMedCrossRef Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281PubMedCrossRef
22.
go back to reference Finn RS, Dering J, Ginther C et al (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105:319–326PubMedCrossRef Finn RS, Dering J, Ginther C et al (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105:319–326PubMedCrossRef
23.
go back to reference Wakeling AE (2005) Inhibitors of growth factor signalling. Endocr Relat Cancer 12 (Suppl 1):S183–S187 Wakeling AE (2005) Inhibitors of growth factor signalling. Endocr Relat Cancer 12 (Suppl 1):S183–S187
24.
go back to reference Hoadley KA, Weigman VJ, Fan C et al (2007) EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8:258PubMedCrossRef Hoadley KA, Weigman VJ, Fan C et al (2007) EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8:258PubMedCrossRef
Metadata
Title
Clinicopathological features of triple-negative breast cancer in Taiwanese women
Authors
Kuo Yao-Lung
Chen Dar-Ren
Chang Tsai-Wang
Publication date
01-10-2011
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 5/2011
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-011-0211-9

Other articles of this Issue 5/2011

International Journal of Clinical Oncology 5/2011 Go to the issue

Introduction to Review Articles

Current topics in colorectal liver metastasis

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine